Paolo Tarantino contrasts historical and current first-line outcomes in HER2 positive metastatic breast cancer, arguing improved understanding and therapies have dramatically extended median progression-free survival.
Median PFS with standard first line treatments in HER2+ MBC: 4 months with chemo (2001), 40 months with T-DXd/P (2025).
Same disease, improved understanding, better treatments!
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare